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BACKGROUND: In patients with advanced ovarian cancer (OvCa), microscopic residual tumour nodules that remain after surgical
debulking frequently escape detection by current treatment assessment methods and lead to disease recurrence. The aim of this
study was to evaluate the use of high-resolution fibre-optic fluorescence imaging of the clinically approved photodynamic therapy
(PDT) agent benzoporphyin-derivative monoacid ring A (BPD-MA) for detection of microscopic OvCa and for monitoring treatment
response.
METHODS: Our fluorescence microendoscope consists of a flexible imaging fibre coupled to a custom epi-fluorescence system
optimised for imaging BPD-MA, which, after a single administration, serves as both an imaging agent and a light-activated therapeutic
agent. After characterisation in an in vitro OvCa 3D model, we used the flexible imaging fibre to minimally invasively image the
peritoneal cavity of a disseminated OvCa murine model using BPD-MA administered intraperitoneally (i.p.). To evaluate longitudinal
changes in response to treatment, we compared sets of images obtained before and after PDT with those from untreated mice
imaged at the same time points.
RESULTS: By comparison with histopathology, we report an 86% sensitivity for tumour detection in vivo using the microendoscope.
Using a custom routine to batch process-image data in the monitoring study, treated mice exhibited an average decrease of 58.8% in
tumour volumes compared with an increase of 59.3% in untreated controls (Po0.05).
CONCLUSIONS: Our findings indicate the potential of this approach as a reporter of treatment outcome that could aid in the rational
design of strategies to mitigate recurrent OvCa.
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In this study, we demonstrate the capability of a custom-built
fluorescence microendoscope to sensitively detect microscopic
ovarian cancer (OvCa) tumour nodules and monitor treatment
response in vivo. This effort is motivated by a vital clinical need for
improved reassessment imaging for this disease. The dismal
survival rates for OvCa are largely because of the high proportion
of patients diagnosed at a late stage, which is characterised by
disseminated nodular studding throughout the peritoneal cavity
and presents challenges for treatment (Jemal et al, 2008; Cho and
Shih, 2009). Despite initial responses to standard tumour
debulking and chemotherapy, many of these patients continue to
harbour occult disseminated disease without immediate clinical
evidence of tumour recurrence because of the microscopic size of
residual nodules (Berek and Bast, 2003). Second-look laparotomy
allows the surgeon to check for persistent residual tumours,
although even this highly invasive surgical reassessment suffers
from a false-negative rate of up to 50% (Selman and Copeland,
1999; DiSaia and Creasman, 2002). These laparotomies are
typically performed 6 months to 2 years after treatment, at which
point, persistent disease, if present, has progressed to the point
that is readily evident to the surgeon and the possibility of an
earlier intervention has been precluded. Non-invasive diagnostic
techniques, such as CA125 levels, ultrasound, computerised
tomography, magnetic resonance imaging (MRI), and positron
emission tomography (PET), which could in principle provide the
benefit of more timely feedback, have all been shown to be less
sensitive than reassessment surgeries (Pectasides et al, 1991;
Sugiyama et al, 1996; Selman and Copeland, 1999; Morrow, 2000;
Rose et al, 2001; Tammela and Lele, 2004). Hence, there is a vital
un-met need for a new minimally invasive imaging approach with
sufficient sensitivity and resolution to detect sub-millimetre OvCa
nodules early in the treatment cycle, thus providing the basis for
more timely interventions to mitigate recurrent disease.
To address the above requirements, several key features of
optical imaging warrant consideration, including its inherently
high resolution and the ability to achieve greater specificity by use
of fluorescent contrast agents (Prasad, 2003; Vo-Dinh, 2003).
Furthermore, technological advances in fibre optic fluorescence
imaging, a modality that allows investigators to reach into body
cavities through minimally invasive endoscopes, have considerably
broadened the applications of in vivo optical imaging (Gmitro and
Aziz, 1993; MacAulay et al, 2004; Flusberg et al, 2005). Although
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ssecond-look laparoscopy by white light imaging has received
significant attention as a minimally invasive procedure to detect
OvCa recurrence (Davila and Estape, 2001), it suffers from a high
false-negative rate of 55% (Ozols et al, 1981) and also fails to
provide the requisite optical resolution and sensitivity to detect the
smallest residual tumours.
An approach to OvCa detection that has shown promise is the
use of photosensitisers (PS), traditionally used for photodynamic
therapy (PDT), to generate tumour-selective fluorescence contrast.
Although fluorescence imaging of non-therapeutic imaging agents
has also shown impressive potential for OvCa detection (Sheth
et al, 2009), PS imaging offers a unique advantage. Upon
wavelength-specific activation of the PS, fluorescence emission
for diagnostic imaging and cytotoxic species (through intersystem
crossing to the triplet state) for tissue destruction can both be
produced. Previous studies that used PS (ALA-induced proto-
porphyrin IX and/or hexaminolaevulinate) for OvCa imaging were
successful in detecting significantly more lesions than white light
imaging (Chan et al, 2002; Ludicke et al, 2003; Loning et al, 2004),
with a ratio of fluorescence intensity of neoplastic to normal
tissues of B4 (Chan et al, 2002; Ludicke et al, 2003). The average
size of the optically biopsied metastatic lesions was 1.0mm (range:
0.3–2.5) compared with 1.5mm (range: 0.5–2.9) with white light
illumination (Chan et al, 2002). However, in the absence of
instrumentation for high-resolution in vivo microscopy in these
studies, the smallest occult nodules (o300mm) were not within the
reported size range.
It is our thesis that if the demonstrated capability of PS
fluorescence for detection of OvCa nodules is combined with
high-resolution fibre-optic microscopy, it would allow for highly
sensitive and minimally invasive detection of microscopic disease.
To this end, we developed a custom fluorescence microendoscope
(Figure 1) optimised for imaging the weak fluorescence emission
from benzoporphyin-derivative monoacid ring A (BPD-MA)
(delivered in its liposomal formulation known as verteporfin or
Visudyne). BPD-MA is clinically approved as a therapeutic PDT
agent and is used in our study to provide both diagnostic and
therapeutic capabilities after a single administration. This inherent
capability to integrate imaging and PDT treatment, which makes
PS imaging particularly conducive to online monitoring of therapy
response, was not used in the studies referenced above. It is also
worth noting that the application of PDT to the treatment of OvCa
has shown promise in clinical trials (Sindelar et al, 1991; Hendren
et al, 2001; Hahn et al, 2006), although further studies are
warranted to establish optimal conditions for light and PS delivery
in the clinic.
The goal of this study was to explore the potential of our
fluorescence microendoscope to detect disseminated small volume
OvCa tumour nodules and provide more accurate and timely
treatment response information than current technologies. We
present characterisation of our system in vitro, using an OvCa 3D
model system (I Rizvi*, JP Celli*, CL Evans, A Abu-Yousif,
T Hasan. Adherent ovarian carcinoma cells migrate and assemble
in vitro into heterogeneous 3D micronodules with differential
treatment response. Manuscript in preparation, to be submitted.
*Equal contribution), and in vivo, using an established mouse
model of disseminated OvCa (Molpus et al, 1996a), both of which
were previously developed in our laboratory. To further demon-
strate the capability of our system to monitor treatment response,
we conducted endoscopic assessment before and after a single PDT
treatment. In this study, PDT serves as a therapy with a variable
level of cytotoxicity to provide a suboptimal dosage conducive for
monitoring therapeutic efficacy.
As proof of principle, this study illustrates the significant
translational potential of fluorescence microendoscopy for detec-
tion of OvCa. Specifically, this method could provide the clinician
with the capability to obtain more timely and accurate treatment
response feedback, which could be used to optimise treatment
parameters to better predict, and hence mitigate, adverse
treatment outcomes. Moreover, the capability to detect sub-
millimetre tumour nodules suggests the potential utility of
fluorescence microendoscopy in early detection of OvCa, if
combined with serum-based or other screening tests to identify
candidates for endoscopic examination.
MATERIALS AND METHODS
Fluorescence microendoscope
For this study, a fluorescence microendoscope with the following
features was required: a miniature and flexible probe providing
minimally invasive access and easy manoeuvering in the mouse
intraperitoneal cavity, and imaging components suited for
fluorescence imaging of BPD-MA, namely, a light source to excite
BPD-MA efficiently, and a highly sensitive camera capable of real-
time imaging of weak fluorescence emission in the 690–700nm
spectral window (Aveline et al, 1994). Although previous studies
have successfully implemented commercially available endomicro-
scopes (Laemmel et al, 2004; Becker et al, 2007; Leung et al, 2009),
none of these systems were well suited for BPD-MA imaging,
lacking either excitation at an appropriate wavelength, sufficient
sensitivity for detection of weak fluorescence emission at 700nm,
and/or having too large a probe for imaging inside a mouse. For
these reasons, we instead built an instrument specifically designed
for this study (Figure 1), similar to custom instruments used by
others in gastrointestinal endoscopy applications (Dubaj et al,
2002; Muldoon et al, 2007, 2008), and offering the additional
advantage of ease of adaptation for use with other imaging agents
EMCCD
Lens
Emission filter
Dichroic mirror
Catheter
Fibre-optic bundle
inside of the mouse
Objective
LED
Lens
Figure 1 Schematic of the fibre-optic fluorescence microendoscope
imaging system.
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sin future studies. The excitation source was a light-emitting diode
(LXHL-LR5C, Luxeon Star LEDs, Brantford, ON, Canada) with an
emission peak at 455nm, well suited to excite the Soret band of
BPD-MA without the use of an additional filter. The LED light was
collimated and directed into an infinity-corrected  10 objective
(NT46-144, Edmund Optics, Barrington, NJ, USA) through
a dichroic mirror (51008bs, Chroma Technology Corp.,
Rockingham, VT, USA). The beam was focused onto the proximal
end of a 1.5m-long, 0.8mm in diameter, 0.35 NA flexible fibre
probe (IGN-08/30, Sumitomo Electric USA Inc., Torrance, CA,
USA) and transmitted to the distal end, delivering an optical power
of 35mW during contact mode imaging of the sample. The
coherent fibre bundle consists of a total of 30000 cores. The core-
to-core spacing, which, for contact mode imaging, dictates the
optical resolution, is about 4.4mm, sufficient for detection of the
presence of microscopic disease at the single cell level as required
for this study. After sample excitation, fluorescence emission was
collected by the fibre probe and sent through the objective, the
dichroic mirror, and an emission filter (D700/40, Chroma
Technology Corp.). A tube lens mounted below the camera forms
the image from the objective while preserving approximately  10
magnification of the fibre probe face on the sensor of the electron-
multiplying CCD camera (Cascade 512B EMCCD, Photometrics,
Tucson, AZ, USA). The Cascade 512B EMCCD was selected for this
study for its high sensitivity in the spectral region of the BPD
fluorescence emission peak. With a 90% sensitivity at 690–700nm,
this provides a significant advantage over a scanning-based
system, by relying on a photomultiplier tube that, even with
extended red performance, provides a quantum efficiency of only
B15% in this spectral region. The EM gain and exposure time
were fixed at 3000V and 30ms, respectively, throughout the
experiments. All images were obtained using 2 2 binning of
pixels to increase the signal-to-noise ratio for quantitative
measurements and to allow for higher speed image acquisition
to reduce blurring artefacts because of motion of the mouse and
the hand-held fibre probe.
Photosensitiser
A liposomal formulation of BPD-MA, also known as verteporfin
(Visudyne, QLT Inc., Vancouver, BC, Canada), was used for this
study. BPD-MA has been approved for use in the clinic by the Food
and Drug Administration (FDA) and is under clinical trial for use
with ovarian cancer. All work involving BPD-MA was conducted
under conditions of minimal room lighting.
OvCa cell cultures
The established NIH, OVCAR5 cell line, was obtained from the Fox
Chase Cancer Institute (Philadelphia, PA, USA) (Hamilton et al,
1984). Cells were grown in RPMI-1640 media supplemented with
10% heat-inactivated FCS, 100Uml
 1 penicillin, and 100mgml
 1
streptomycin and maintained in an incubator at 371Ci n5 %C O 2.
Building on 3D breast cancer models introduced by Bissel et al
(Petersen et al, 1992; Muthuswamy et al, 2001; Debnath et al,
2003), we recently developed a 3D in vitro model of micrometa-
static OvCa (I Rizvi*, JP Celli*, CL Evans, A Abu-Yousif, T Hasan.
Adherent ovarian carcinoma cells migrate and assemble in vitro
into heterogeneous 3D micronodules with differential treatment
response. Manuscript in preparation, to be submitted. *Equal
contribution). Briefly, OVCAR5 cells were seeded as a single-cell
suspension on a bed of growth factor reduced matrigel and
spontaneously formed 3D acinar structures resembling micro-
nodular ovarian cancer. The cells were grown in an assay medium
containing OVCAR5 cell culture media, 5ngml
 1 epidermal
growth factor, and 2% Matrigel, and formed tumour nodules up
to hundreds of microns in size, which served as an in vitro model
of OvCa metastases.
Fluorescence imaging of cell cultures
OVCAR5 cells in monolayer and 3D culture were incubated
in 1.0mM BPD-MA diluted in the appropriate culture media
described above to prepare for fluorescence imaging. For the
time course experiment, 3D culture dishes were removed from
incubation at time t (t¼1, 4, 20, and 24h) and imaged with the
fluorescence microendoscope. Thereafter, 2ml of dispase (354235,
BD Biosciences, Bedford, MA, USA) was added to each dish to
recover cells from Matrigel and to form a single-cell suspension.
After 2h, the cell solution was collected, along with 2ml of media
used to rinse the dish and collect any remaining cells, as well as to
stop the dispase-catalysed reaction. The numbers of cells in each
solution was counted using a haemocytometer. Cell suspension
of 100ml was added to a well in a 96-multi-well plate. Fluorescence
measurements were then obtained using a plate reader at 436nm
excitation and 690nm emission. To convert the fluorescence
measurement obtained from the samples into a concentration of
BPD-MA, a calibration curve was created using cell suspensions
mixed with known concentrations of BPD-MA. For each of the four
time points studied, data were generated from two independently
plated 3D cultures.
Animal model
We used an OvCa mouse model previously developed in our
laboratory to mimic human disseminated ovarian carcinoma
(Molpus et al, 1996b). Female Swiss nude mice (Cox, Cambridge,
MA, USA), 6–8-weeks old, were injected intraperitoneally (i.p.)
with cultured OVCAR5 cells at an initial inoculum of 3.15 10
7
cells in single-cell suspension in PBS. They had continual access to
food and water while being housed in laminar flow racks under
specific pathogen-free conditions. All animal procedures, including
killing by CO2 inhalation, were conducted in accordance with
institutional guidelines for research animal care.
In vivo imaging of tumours
We performed fluorescence microendoscopy in the OvCa mice at
3–4 weeks after tumour inoculation. Each mouse was injected
i.p. with 1mgkg
 1 body weight of BPD-MA and imaged under
anaesthesia with the fibre probe introduced into the peritoneal
cavity through an incision made in the abdominal wall. For
comparison between microendoscope image data and pathological
analysis, tissues at different anatomical sites were biopsied
immediately after imaging before the mice were killed by CO2
inhalation. Resected tissue was fixed in 10% phosphate-buffered
formalin and embedded in paraffin. Sections of 5um thickness
were stained with haematoxylin–eosin for microscopic assessment.
In vivo treatment monitoring
OvCa mice were imaged at days 14 and 19 after tumour
inoculation. Mice were randomly assigned to treatment and
no-treatment control groups. Additional mice, which were not
inoculated with tumour cells, were imaged at the same time points
for healthy tissue comparison. All mice in the longitudinal
monitoring study were injected with a therapeutic dose of
0.25mgkg
 1 body weight of BPD-MA i.p. 75min before each
imaging session, which was conducted minimally invasively by
introducing the fibre probe into the i.p. cavity of the supine
anaesthetised mouse through a 14-gauge catheter to traverse the
abdominal wall. Sets of images of the pelvic omentum (5 images
per side) and the peritoneal wall (10 images per quadrant) were
obtained for each mouse at both time points while the fibre was
cleaned frequently in water to remove debris from the tip. Mice
that received treatment were injected with 2ml of 0.1% intralipid
solution (Intralipid Soybean Oil Emulsion; Baxter Healthcare
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sCorporation, Deerfield, IL, USA) and each peritoneal quadrant was
irradiated 90min after BPD-MA injection with 6.25Jcm
 1 of a
1cm cylindrical diffusing tip fibre at 690nm and an irradiance of
150mWcm
 2 (calibrated by an integrating sphere), as described
earlier (Molpus et al, 1996a), for a total light dose of 25Jcm
 1.
Further details of the i.p. PDT treatment procedure are illustrated
in Supplementary Figure 1. After the first imaging session (day 14)
and treatment (when applicable), mice were allowed to wake up
and resume their normal diet and activity. On completion of the
second imaging session (day 19), mice were killed by CO2
inhalation so that tissues could be retained for pathological
analysis as described above.
Data analysis
Fluorescence images were obtained and processed by IPLab (BD
Biosciences – Bioimaging Division, Rockville, MD, USA) and
Matlab (The MathWorks Inc., Natick, MA, USA). To eliminate
background because of the bias level set by the camera
manufacturer and the leakage of reflected excitation light through
the emission filter, we subtracted from each image the background
image measured from water with zero fluorescence. We also
compensated for the non-uniform spatial response of the system
by normalising the background-subtracted images with an image
from a uniform solution of 1mM BPD-MA. Both water and 1mM
BPD-MA solutions were freshly prepared and imaged at the
beginning of each imaging session. Pixel values within each image
were calibrated as follows:
Iðx;yÞ¼
I0ðx;yÞ Iwðx;yÞ
ðIBPD MAðx;yÞ Iwðx;yÞÞ=MeanðIBPD MAðx;yÞ Iwðx;yÞÞ
ð1Þ;
where I0, Iw, and IBPD-MA are the raw images of a sample, water,
and 1mM BPD-MA solution, respectively. Mean represents the
mean value of all pixels (N) within the endoscope’s field of view
(0.8mm in diameter). This normalisation term minimises
sensitivity variation because of occasional system realignment.
The fluorescence intensity of BPD-MA in the 3D cultures of
tumour nodules was calculated as follows. First, individual tumour
nodules were identified by segmentation on the basis of selection
of pixels with intensity values above a threshold that corresponded
to background fluorescence from the culture media containing
BPD-MA. Segmentation was based on the triangle algorithm,
which was readily available as a built-in utility of the IPLab
software package. In this technique, a line connecting the
minimum and maximum values in the histogram of intensities
of all pixels in an image is established. The distances between the
line and all intensity values are computed. The intensity value that
has the shortest distance to the line is set as the threshold value for
separating objects from the background. The fluorescence
intensity of each segmented nodule was calculated by spatial
averaging over all interior pixels. The same segmentation approach
was used to outline tumour nodules of OvCa mice for the purpose
of size determination in vivo.
For the treatment monitoring study, in which large sets of
images were processed before and after treatment, mean BPD-MA
fluorescence values were calculated by means of custom scripts to
batch-process entire directories of data. For each image, mean
fluorescence intensity was determined by averaging all pixels
within the circular field of view of the endoscope. The field of view
was automatically determined in each image (to account for slight
displacements of the field of view with respect to the CCD chip)
using a custom routine that uses a combination of a wavelet
transform-based edge detection and circle detection algorithms.
This mean value was corrected for the background level as
described above and normalised to 1mM BPD-MA control
solution. Normalised values were grouped by site (pelvic omentum
or peritoneal wall) for each mouse at each time point to calculate
the overall mean for each site and the percentage change in
fluorescence intensity at that site from day 14 to 19 as described
further below.
RESULTS
Validation of fluorescence imaging in cell cultures
To establish the capability of our fluorescence microendoscope
to resolve single cells, we first imaged OVCAR5 cells grown
in monolayer and incubated with BPD-MA for 4h (Figure 2).
Our instrument was able to resolve individual cells. The ability
to observe some degree of subcellular structure is consistent
with our estimate of a 4.4mm optical resolution based on the
spacing of fibre cores noted above. Within individual cells,
the diffuse pattern of BPD-MA fluorescence localised to the
cytoplasm is characteristic of the intracellular distribution of
BPD-MA observed in previous studies (Figure 2B and C) (Osaki
et al, 2006).
To establish our instrument’s capability for quantitative
measurements, BPD-MA fluorescence intensity from in vitro 3D
tumour cultures was correlated with nodule size and fluorescence
from disaggregated 3D nodules. Figure 3A is a representative
image of 3D cultures of tumour nodules imaged 24h after
incubation in BPD-MA. As anticipated, the integrated BPD-MA
fluorescence signal fluorescence from tumour nodules was found
to increase with nodule size (Figure 3B). A power law curve fit
indicated a relationship given by I a a
k, where a is the nodule area
(in our 2D image) and k¼1.27. This power law scaling is within
reason for the characteristics of our model and light collection. We
would expect k¼1 for clusters of monolayer cells in which case
light would be collected from an essentially flat plane with
intensity scaling linearly with the area (determined by the number
of cells in the cluster). For the ideal scenario of total light collection
from the full volume of perfectly spherical clusters of cells, we
would expect intensity to scale with area to the 3/2 power (k¼1.5),
corresponding to a linear relationship with volume. The fact that
the measured power law dependence of k¼1.27 lies in between
these two limiting cases is not surprising, in view of the non-3D
light collection from the finite depth of focus of the imaging device,
combined with the fact that the in vitro micronodules are in fact
not perfectly spherical.
A B
C
4×
Figure 2 Fluorescence image of monolayer OVCAR5 cells in vitro
incubated in BPD-MA. (A) Endoscope image. Dotted line indicates the field
of view of 0.8mm. Scale bar is 100mm. (B) Enlarged image of the area
marked in (A) (square). (C) Same as B after removing pixelation and
enhancing contrast by software. The image shows localisation of BPD in the
cytoplasm. Scale bar is 25mm.
Ovarian cancer detection and treatment monitoring
W Zhong et al
2018
British Journal of Cancer (2009) 101(12), 2015–2022 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sAs illustrated in Figure 3C, during the 24h BPD-MA incubation,
there was a time-dependent increase in fluorescence intensity. The
measured data fitted well with an exponential model given as
I¼I0*(1 e
 k*t), where I0¼3.1 10
4 and k¼0.12 (Figure 3C). To
validate that the fluorescence intensities measured by the
microendoscope were reflective of the actual BPD-MA concentra-
tions in the 3D acini, we disaggregated the in vitro nodules and
measured fluorescence from dissociated cells with a plate reader
and determined concentration by a standard curve. Figure 3D
illustrates the strong correlation between fluorescence intensities
as measured by the microendoscope and the plate reader. A linear
fit of these two independent measurements gave a Pearson’s
coefficient of regression R
2¼0.84.
In vivo imaging of micrometastases
Microscopic tumour nodules were identified during imaging
sessions by slowly scanning the tip of the fibre probe over
peritoneal surfaces inside anaesthetised mice and acquiring images
with particular emphasis on the pelvic and subgastric omenta, the
peritoneal wall, and the bowel mesentery, known to have high rates
of tumour occurrence. To determine the size of the microscopic
tumour nodules detected, images obtained in the mouse i.p. cavity
were compared with the pathological analysis of tissues resected
from the same sites. Figure 4 shows a fluorescence image (A–C)
and H & E stain (D) of a section obtained from the same tissue.
This result indicates that fluorescence endoscopy can detect
tumour nodules as small as a few tens of microns (arrows).
We compared the fluorescence images of 171 samples biopsied
from eight OvCa mice with the results of pathological analysis.
Microendoscopic images and correspsonding histopathology
specimens were assessed by an investigator to identify samples
that were positive for tumour, as identified by the presence of any
visible nodules. Of the 141 samples determined to be neoplastic by
pathological analysis, 121 showed evidence of tumour nodules by
fluorescence microendoscopy, with each tumour-positive field/
specimen being weighted equally, regardless of the number of
nodules. Of the 30 samples determined to be normal by
pathological analysis, 16 seemed to be tumour free by fluorescence
microendoscopy. Hence, with BPD-MA as the contrast agent, the
sensitivity and specificity of fluorescence microendoscopy for
detecting tumour nodules were 86% and 53%, respectively.
Monitoring of PDT treatment response
Having established the capability of our fluorescence microendo-
scope for sensitive detection of OvCa, we conducted a pilot study
to evaluate the potential of our technique to serve as a quantitative
reporter of therapeutic response. OvCa mice were imaged
immediately before PDT treatment, or control injection of PS, at
14 days after tumour inoculation and reassessed at day 19 (at
which point only the day 19 reinjection is relevant to the measured
PS fluorescence signal because of the rapid clearance rate of BPD-
MA from peritoneal tissues, which is reported in Supplementary
Figure 2). Representative images obtained at each time point from
mice in each treatment group and from non-tumoured control
mice are shown in Figure 5. To quantitatively evaluate the
observed changes in treated and untreated mice, it was necessary
to develop a robust method for minimally invasively surveying
disseminated OvCa, in which tumour nodules are spread in an
inhomogeneous manner over a large surface area in the i.p. cavity.
To achieve this while minimising sampling bias, we took the
approach of acquiring large sets of image data and developed a
batch-processing technique to generate distributions of BPD-MA
fluorescence intensities by region. For each mouse, at each time
point, we obtained sets of images of 40 sites on the visceral
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Figure 3 Validation of fluorescence imaging in 3D cultures. (A) Representative fluorescence image of 3D culture of tumour nodules incubated in BPD-
MA. Scale bar is 100mm. (B) Fluorescence intensity of BPD-MA in tumour nodules plotted against nodule size. The plotted data are fit to a power law (line)
with k¼1.27, with R
2¼0.94. (C) Uptake of BPD-MA by 3D cultures over time measured with the fluorescence microendoscope. The error bars represent
standard deviations. The trend line is a single exponential fit. (D) Uptake of BPD-MA by 3D cultures over time measured with the fluorescence
microendoscope vs plate reader measurements from cells of the same disaggregated tumour nodules. The linear regression, represented by the solid line,
suggests the consistency between these two methods.
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speritoneum, divided equally over 4 quadrants, and 10 sites on the
pelvic omentum, over both sides of the pelvis. We then tracked
changes in BPD-MA fluorescence intensity as a reporter of tumour
nodule volume, building upon the correlation established above
from our 3D tumour model (Figure 3). Normalised fluorescence
intensities from each image determined by batch-processing
directories of image data were grouped and further processed to
calculate the average measured percentage tumour regrowth (or
destruction as indicated by a negative percentage) by site for
untreated and PDT-treated mice (Figure 6). This approach,
although not taking full advantage of the 2D image data provided
by the endoscope, provided a robust means of quantifying disease
progression while avoiding potential pitfalls of extensive auto-
mated manipulation of large sets of image data to count and
measure individual nodules in sets of images. The latter could be
especially problematic in cases in which the disease becomes caked
to completely fill the microendoscope field of view (particularly in
the omentum tissue), in particular while imaging with a lower-
contrast therapeutic dose of BPD-MA.
Our microendoscopy imaging and analysis reports that disease
developed unchecked in untreated mice, with positive mean
percent changes from day 14 to 19 of þ59.3% and þ17.7% for the
pelvic omentum and peritoneal wall, respectively (Figure 6A). In
treated mice, this trend is reversed with negative values of
regrowth (indicating mean tumour destruction) of  58.8% and
 30.2% in the same sites, consistent with the modest, single dose
of PDT applied here. Comparison of treatment and control groups
on the basis of images from the pelvic omentum was clearly
significant with a P-value of 0.027 (two-tailed Student’s t-test), in
contrast to the comparison based on peritoneal wall images with a
P-value of 0.21. The larger separation in response between treated
and untreated groups on the basis of images of the pelvic omentum
is likely because of a higher rate of proliferation for cells implanted
on these energy-rich fat pads relative to the peritoneal wall, leading
to more significant growth in the untreated group during the
time between imaging sessions. Conversely, in treated mice, the
lipophilicity of verteporfin may have led to larger local accumula-
tion of BPD-MA in the microenvironment of those tumour nodules
that are surrounded by fatty tissues, thus leading to a higher local
cytotoxic effect in the pelvic omentum and further enhancing
significance in measured treatment response. In addition, some
level of variability in tumour aggressiveness and response to
treatment from mouse to mouse is typical of this model of
disseminated OvCa (Molpus et al, 1996a,b). In the images
obtained from tumour-free mice, there was no significant change
in fluorescence intensity between imaging sessions for either of the
sites probed.
The bottom two panels of Figure 6 detail the calculation of the
change in BPD-MA fluorescence between the two imaging time
points from a given untreated mouse (Figure 6B) and PDT-treated
mouse (Figure 6C) used in the calculation of group averages. These
histograms were prepared by grouping intensity values from
individual images into bins of width 0.05 and plotted as relative
frequency of files occurring in a particular bin vs normalised
intensity. The image-to-image fluctuations in intensity at each time
point reflect the spatial variation in nodular studding and
AB
4×
D
C
Figure 4 In vivo detection of micrometastases. (A) Fluorescence image of small tumour nodules (tens of microns in size) detected in OvCa mouse by the
fluorescence microendoscope using BPD-MA as the contrast agent. (B) Enlarged image of the area marked in (A) (square). (C) Contrast-enhanced image of
(B). Four high-intensity spots (circles) are observed. (D) H & E stain of a 5mm-thick section from the same region. Arrows indicate tumour nodules. Scale
bars are 100mmi n( A) and (D), and 25mmi n( C).
AB
CD
EF
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Figure 5 Representative longitudinal monitoring microendoscopic
images from the peritoneal wall of treated, untreated, and normal mice
at days 14 and 19 shown with an intensity scale for comparison. (A, B)
Images from a PDT-treated mouse at days 14 and 19, respectively. (C, D)
Images from an untreated mouse at days 14 and 19. (E, F) Images from a
normal (non-tumour bearing mouse) at days 14 and 19. In general, the
intensity of BPD-MA fluorescence was observed to decrease from day 14
to 19 in mice that received PDT treatment, whereas the opposite trend
was evident in untreated mice. Microendoscopic images obtained from
normal mice showed low levels of fluorescence intensity independent of
the imaging time point.
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soccasional regions of more caked disease encountered by the fibre
probe as it scanned over peritoneal surfaces. The Gaussian fits to
the distributions of fluorescence intensities at each time point
indicate the calculation of the mean value that increases from day
14 to 19 for the untreated mouse (indicating uninterrupted tumour
growth) in Figure 6B. In contrast, the shift of the distribution of
fluorescence intensities towards lower values from day 14 to 19 for
a mouse that received PDT treatment in Figure 6C shows some
tumour destruction for a PDT dose of 25Jcm
 1.
DISCUSSION
In this study, we show the ability of a custom fluorescence
microendoscope to detect OvCa micrometastases on the order of
tens of microns in diameter (Figure 4) – a feature that has not been
shown by conventional imaging modalities such as ultrasound,
MRI, or PET. We note that this size is an order of magnitude
smaller than those found in previous reports describing PS
fluorescence imaging in OvCa animal models or patients (Chan
et al, 2002). In the context of treatment assessment, the ability to
detect such small nodules could be invaluable to clinicians by
providing feedback early in the treatment cycle rather than having
to wait until nodules have become large enough for detection by
laparoscopy or surgical reassessment, at which point the disease
has advanced to a stage with poor prognosis. The microendo-
scope’s high sensitivity (86%) to tumour nodules, which translates
to a false-negative rate of 14% as compared with 31% reported for
white light imaging in a similar murine model (Sheth et al, 2009),
may hold the key to a more effective detection of OvCa.
Our choice of BPD-MA, a potent photosensitiser, as a
fluorescence contrast agent made PDT treatment a useful
therapeutic tool to assess the treatment monitoring capability of
the instrument, enabling us to treat and monitor response using
the same molecule. Using BPD-MA in this dual role as a
therapeutic and sensitive tumour recognition agent, we show the
potential of our technique to serve as a quantitative tool to evaluate
acute response to treatment using fluorescence as a reporter of
tumour volume. We observed evidence of tumour destruction in
mice that received PDT treatment, whereas untreated mice showed
uninterrupted progression of disease from microendoscopy of the
pelvic omentum, as well as the peritioneal wall. The challenges of
sampling the large surface area of the latter site suggest the benefits
of incorporating this technology with traditional white light
laparoscopy, which is already in clinical use. In fact, because of
the flexible imaging fibre used in the microendoscope, the two
methods could be highly complementary. One could imagine a
clinician seamlessly going back and forth between the laparoscope
and the microendoscope, with the wide field imaging of the former
providing a cursory identification of suspicious regions to be
further interrogated with higher sensitivity and microscopic details
using the microendoscope. The diagnostic efficiency of fluores-
cence microendoscopy, which, as with any epi-fluorescence-based
detection strategy, is limited in its ability to penetrate below the
tissue surface, could be further enhanced by integration with a
complementary imaging modality to provide depth-resolved
structural information.
Our results specifically indicate the promise of fluorescence
microendoscopy to fill the vitally needed niche of a minimally
invasive technique for treatment monitoring. To follow-up on
these findings, further studies are warranted to extend these
findings from the acute treatment response examined here to
assess the capability of this technique to predict long-term
outcomes to more extensive therapeutic regimens in survival
studies. It should be further noted that, although our use of a PS
made PDT a convenient modality for testing this technology, this
instrumentation is not specific to monitoring PDT treatment and
could be used in the same capacity as other modalities, including
surgery and chemotherapy.
Future improvements will include the incorporation of targeted
imaging contrast agents to improve specificity for imaging
tumours. However, it is encouraging to note that even while
implementing our fluorescence microendoscope without a targeted
imaging agent, the tumour-to-normal ratios of BPD-MA in
fluorescence images were found to be between 2 and 3, with an
overall sensitivity of 86% for tumour detection. We anticipate that
with the development of more specific tumour-targeted imaging
contrast agents, a substantial improvement in both tumour-to-
normal contrast and specificity will be realised. This is part of an
ongoing effort in our laboratory to develop suitable constructs to
explore the use of nanoparticle formulations to allow a high degree
of customisation in combining fluorescence imaging agents with
appropriate binding sites for specific small molecule targets.
Furthermore, one could envision designing theranostic-targeted
nano-constructs that could carry not only fluorophores but also
therapeutic agents. Such ‘smart’ constructs could be used in
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Figure 6 Treatment-monitoring data. (A) Mean percentage tumour
regrowth for all mice in the treatment and control groups obtained from
sets of images at days 14 and 19 for pelvic omentum (white) and peritoneal
wall (grey). Error bars represent mouse-to-mouse variation. (B) Distribu-
tion of fluorescence intensities from day 14 images (grey bars) to day 19
images (white bars) for a given mouse in the no-treatment group, showing
longitudinal shift to the right (increasing fluorescence intensity). Histograms
were generated by grouping normalised intensity values into bins of width
0.05 and are plotted as relative frequency of occurrence vs intensity (bin
end). (C) Distribution of fluorescence intensities from images of the
peritoneal wall for a given mouse in the PDT treatment group showing a
downwards shift in fluorescence intensity as compared with the no-
treatment control. Distributions in (B) and (C) are obtained from 40
measurements per time point, per mouse.
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sconjunction with fluorescence microendoscopy for the diagnostic
therapy of cancer (Sumer and Gao, 2008).
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